All In Biotech

Drug Trial Radar · NCT05262023

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Actual

Start

Feb 1, 2022

Primary completion

Dec 2026

Study completion Nov 2028

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Takeda
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.

Conditions

  • Frontotemporal Dementia

Interventions

  • DNL593Drug

    Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

  • PlaceboDrug

    Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)Time frame: up to 18 months
  2. Incidence of treatment-emergent clinically significant abnormalities in safety laboratory valuesTime frame: up to 18 months
  3. Change from baseline in vital sign measurements: systolic and diastolic blood pressureTime frame: up to 18 months
  4. Change from baseline in vital sign measurements: heart rateTime frame: up to 18 months
  5. Change from baseline in vital sign measurements: respiratory rateTime frame: up to 18 months
  6. Change from baseline in vital sign measurements: body temperatureTime frame: up to 18 months
  7. Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTcF intervalsTime frame: up to 18 months
  8. Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findingsTime frame: up to 18 months
  9. Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only)Time frame: up to 18 months

Locations

26 sites in 12 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • John Hopkins University

    Baltimore, Maryland

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Antwerp

    Antwerp, Belgium

  • UZ Leuven

    Leuven, Belgium

  • L2IP - Instituto de Pesquisas Clinicas LTDA

    Brasília, Brazil

  • Faculdade de Medicina Da Universidade de São Paulo

    São Paulo, Brazil

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Grupo de Neurosicencias de la Universidad de Antioquia

    Medellín, Colombia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • CHU de Nantes

    Nantes, France

  • CHU Rouen

    Rouen, France

  • CHU Toulouse

    Toulouse, France

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • IRCCS Istituto Auxologico Italiano

    Milan, Italy

  • Azienda Ospedaliera Cardinale G Panico

    Tricase, Italy

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Hospital de Braga

    Braga, Portugal

  • Campus Neurológico Sénior

    Torres Vedras, Portugal

  • Hospital Clinic de Barcelona

    Barcelona, Barcelona, Spain

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Guipúzcoa, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, Spain

  • Istanbul University Istanbul Medical Faculty

    Istanbul, Turkey (Türkiye)

  • Ondokuz Mayis University Hospital

    Samsun, Turkey (Türkiye)

  • Simbec Orion

    Merthyr Tydfil, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.